Norelut tablets
Dexa Medica
Ingredients in every tablet
| Norethisterone | 5 mg |
Each package contains
5 strips of 10 tablets
Dosage form
 |
tablet |
Dosage formTablet; plain
Flavour
None
W.H.O. classification
G03A
G03A
A.T.C. Level 1
Anatomical Main group
G - Genito-urinary system and sex hormones
G03A
A.T.C. Level 2
Therapeutic subgroup
G03 - Sex Hormones and Modulators of the Genital System
G03A
A.T.C. Level 3
Pharmacological subgroup
G03A - Hormonal Contraceptives for Systemic Use
Available in
 |
Indonesia |
Warnings
Alcohol
CONSULT YOUR DOCTORSafety of this item for use with alcohol has not been established. Please consult your doctor.
Machinery
SAFE IF PRESCRIBEDThis item is safe for use while operating heavy machinery.
Pregnancy
NOT RECOMMENDEDThis item is not safe for use during pregnancy.
Lactation
CONSULT YOUR DOCTORSafety of this item for use during lactation has not been established. Please consult your doctor.
Indication
Treatment of amenorrhea, abnormal uterine bleeding caused by hormonal imbalance without organic abnormalities such as submucous fibroids or uterine cancer and endometriosis.
Dosage
FOR ALL AGES
Before using this drug, a general health examination and a gynecological examination (including a breast and pelvic examination) must be carried out carefully and be ensured first that the patient is not pregnant.
Amenorrhea and uterine bleeding
Therapy with this drug must be adjusted to the specific indication and therapeutic response of each patient. For amenorrhea therapy or abnormal uterine bleeding, the menstrual cycle is estimated at 28 days. The first day of bleeding is counted as the first day of the cycle. Therapy begins on the 5th day of the menstrual cycle and continues until the 25th day.
Dosage: 5-20 mg a day.
Endometriosis
For endometriosis therapy, the initial dose is 10 mg daily for 2 weeks and the dose can be increased 5 mg per day every 2 weeks until the maximum dose is 30 mg per day. Therapy can be continued for 6-9 months; if bleeding persists, therapy must be stopped temporarily.
Before using this drug, a general health examination and a gynecological examination (including a breast and pelvic examination) must be carried out carefully and be ensured first that the patient is not pregnant.
Amenorrhea and uterine bleeding
Therapy with this drug must be adjusted to the specific indication and therapeutic response of each patient. For amenorrhea therapy or abnormal uterine bleeding, the menstrual cycle is estimated at 28 days. The first day of bleeding is counted as the first day of the cycle. Therapy begins on the 5th day of the menstrual cycle and continues until the 25th day.
Dosage: 5-20 mg a day.
Endometriosis
For endometriosis therapy, the initial dose is 10 mg daily for 2 weeks and the dose can be increased 5 mg per day every 2 weeks until the maximum dose is 30 mg per day. Therapy can be continued for 6-9 months; if bleeding persists, therapy must be stopped temporarily.